COMMUNIQUÉS West-GlobeNewswire

CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
27/10/2026
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 Company on track to [...]
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
27/10/2026
CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies [...]
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
27/10/2026
BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Acquisition adds [...]
Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
27/10/2026
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately [...]
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
27/10/2026
Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the platform [...]
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
27/10/2026
Rezdiffra ® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatment persistence in [...]
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
27/10/2026
BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, [...]
AssistRx Named a Central Florida Top Workplace for Sixth Consecutive Year
27/10/2026
Employee feedback-based recognition highlights AssistRx’s focus on growth, inclusion and wellness ORLANDO, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- AssistRx , the advanced therapy initiation and patient solutions [...]
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
27/10/2026
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill [...]
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
27/10/2026
WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti- [...]
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
27/10/2026
Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced receipt of a delisting [...]
Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform
27/10/2026
– Firefly’s AI foundation model, being built on more than 200,000 standardized EEG/ERP brain scans, bolsters its long-term BCI growth opportunity – – With over 3,000 Versus headsets shipped, the platform generates [...]
Meet Patel's Passion Farms Reports 20% Year-Over-Year Growth Across Multi-State Operations
27/10/2026
Houston-based wholesaler reports a 20% revenue increase for the first nine months of 2026, matching the 20% annual growth it recorded in 2024 and 2025 HOUSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Passion Farms , a Houston [...]
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
27/10/2026
Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company [...]
Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET
27/10/2026
HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and [...]
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
27/10/2026
Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers Advancing WVE-007 (INHBE siRNA) across treatment settings [...]
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
27/10/2026
Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be held on November 12-15 [...]
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
27/10/2026
Company’s Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi PHILADELPHIA, Oct. 27, 2026 (GLOBE [...]
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
27/10/2026
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however, [...]

Pages